An official website of the United States government
CPT Codes Mapped to CVX Codes
Email Updates
Subscribe to receive email updates about this page.
This table cross-references Current Procedural Terminology (CPTTM) codes that are related to vaccines, toxoids and immune globulins with their corresponding CVX codes. The goal of the table is to support mapping of CPT codes to CVX codes in systems that receive CPT codes as part of an electronic data exchange. The CVX and/or NDC code systems are highly recommended when exchanging immunization data, but if a sending system must use CPT codes, this table may be used by the receiving system to translate the CPT code to the single best CVX code equivalent. In all cases, the code utilized, be it NDC, CVX or CPT, should be the most specific and granular representation possible of the vaccine given. Where only a single vaccine exists, the CPT code is mapped to that vaccine specific CVX code. However, in many cases, a single CPT code could be used with multiple vaccines utilizing different CVX codes. In this situation, the CPT code is mapped to the "unspecified formulation" CVX code because it is not possible to infer a specific vaccine formulation from the CPT code alone.
This table is not intended to support mapping from CVX to CPT nor to be a definitive source for CPT codes. Practices must approach billing for vaccines (selection of a CPT code for a given administration) independently from recording and reporting the most specific vaccine codes to an IIS or other clinical trading partner. Active CPT codes, inactive CPT codes and pre-release CPT codes are included. Every effort is made to keep the codes current.
Sort Table by Column: Simply click on the column heading to sort the table accordingly.
The Last Updated column indicates the last time this particular CPT code was updated in this table.
| CPT CODE | CPT Description | CVX Code | Vaccine Name | Comments | Last Updated Date |
|---|---|---|---|---|---|
| 90281 | Immune globulin (Ig), human, for intramuscular use | 86 | IG | 6/13/2024 | |
| 90283 | Immune globulin (IgIV), human, for intravenous use | 87 | IGIV | 6/13/2024 | |
| 90287 | Botulinum antitoxin, equine, any route | 27 | botulinum antitoxin | 6/13/2024 | |
| 90291 | Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use | 29 | CMVIG | 6/13/2024 | |
| 90296 | Diphtheria antitoxin, equine, any route | 12 | diphtheria antitoxin | 6/13/2024 | |
| 90371 | Hepatitis B immune globulin (HBIg), human, for intramuscular use | 30 | HBIG | 6/13/2024 | |
| 90375 | Rabies immune globulin (RIg), human, for intramuscular and/or subcutaneous use | 34 | RIG | 6/13/2024 | |
| 90376 | Rabies immune globulin, heat-treated (RIg-HT), human, for intramuscular and/or subcutaneous use | 34 | RIG | 6/13/2024 | |
| 90378 | Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each | 93 | RSV-MAb | 6/13/2024 | |
| 90380 | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use | 306 | RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months | CPT Code to be used for Beyfortus 0.5 mL | 6/13/2024 |
| 90381 | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use | 307 | RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months | CPT Code to be used for Beyfortus 1.0 mL | 6/13/2024 |
| 90389 | Tetanus immune globulin (TIg), human, for intramuscular use | 13 | TIG | 6/13/2024 | |
| 90393 | Vaccinia immune globulin, human, for intramuscular use | 79 | vaccinia immune globulin | 6/13/2024 | |
| 90396 | Varicella-zoster immune globulin, human, for intramuscular use | 36 | VZIG | 6/13/2024 | |
| 90470 | H1N1 immunization administration (intramuscular, intranasal), including counseling when performed | 128 | Novel Influenza-H1N1-09, all formulations | 2/28/2017 | |
| 90476 | Adenovirus vaccine, type 4, live, for oral use | 54 | adenovirus, type 4 | 6/13/2024 | |
| 90477 | Adenovirus vaccine, type 7, live, for oral use | 55 | adenovirus, type 7 | 6/13/2024 | |
| 90581 | Anthrax vaccine, for subcutaneous or intramuscular use | 24 | Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis | 6/13/2024 | |
| 90581 | Anthrax vaccine, for subcutaneous or intramuscular use | 318 | Anthrax, post-exposure prophylaxis | 6/13/2024 | |
| 90585 | Bacillus Calmette-Guerin vaccine (BCG) for tuberculosis, live, for percutaneous use | 19 | BCG | 6/13/2024 | |
| 90589 | Chikungunya virus vaccine, live attenuated, for intramuscular use | 317 | Chikungunya live attenuated vaccine, 0.5 mL, PF | 6/13/2024 | |
| 90611 | Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use | 206 | Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injection | CPT Code to be used for JYNNEOS vaccine | 6/13/2024 |
| 90619 | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use | 203 | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) | 6/13/2024 | |
| 90620 | Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use | 163 | meningococcal B, OMV | 6/13/2024 | |
| 90621 | Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use | 162 | meningococcal B, recombinant | 6/13/2024 | |
| 90622 | Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use | 75 | vaccinia (smallpox) | CPT Code to be used for ACAM2000 vaccine | 6/13/2024 |
| 90623 | Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use | 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | 6/13/2024 | |
| 90625 | Cholera vaccine, live, adult dosage, 1 dose schedule, for oral use | 174 | cholera, live attenuated | 6/13/2024 | |
| 90626 | Tick-borne encephalitis virus vaccine, inactivated; 0.25 mL dosage, for intramuscular use | 223 | Tick-borne encephalitis, inactivated, PF, 0.25mL | 6/13/2024 | |
| 90627 | Tick-borne encephalitis virus vaccine, inactivated; 0.5 mL dosage, for intramuscular use | 224 | Tick-borne encephalitis, inactivated, PF, 0.5mL | 6/13/2024 | |
| 90630 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use | 166 | influenza, intradermal, quadrivalent, preservative free | 9/24/2024 | |
| 90632 | Hepatitis A vaccine (HepA), adult dosage, for intramuscular use | 52 | Hep A, adult | 6/13/2024 | |
| 90633 | Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use | 83 | Hep A, ped/adol, 2 dose | 6/13/2024 | |
| 90634 | Hepatitis A vaccine (HepA), pediatric/adolescent dosage-3 dose schedule, for intramuscular use | 84 | Hep A, ped/adol, 3 dose | 6/13/2024 | |
| 90636 | Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use | 104 | Hep A-Hep B | 6/13/2024 | |
| 90644 | Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae type b vaccine (Hib-MenCY), 4 dose schedule, when administered to children 6 weeks-18 months of age, for intramuscular use | 148 | Meningococcal C/Y-HIB PRP | 6/13/2024 | |
| 90645 | Hemophilus influenza b vaccine (Hib), HbOC conjugate (4 dose schedule), for intramuscular use | 47 | Hib (HbOC) | 2/28/2017 | |
| 90646 | Hemophilus influenza b vaccine (Hib), PRP-D conjugate, for booster use only, intramuscular use | 46 | Hib (PRP-D) | 2/28/2017 | |
| 90647 | Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use | 49 | Hib (PRP-OMP) | 6/13/2024 | |
| 90648 | Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use | 48 | Hib (PRP-T) | 6/13/2024 | |
| 90649 | Human Papillomavirus vaccine, types 6, 11, 16, 18, quadrivalent (4vHPV), 3 dose schedule, for intramuscular use | 62 | HPV, quadrivalent | 6/13/2024 | |
| 90650 | Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, for intramuscular use | 118 | HPV, bivalent | 6/13/2024 | |
| 90651 | Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 165 | HPV9 | 6/13/2024 | |
| 90653 | Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use | 168 | Influenza, adjuvanted, trivalent, PF | 6/13/2024 | |
| 90654 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use | 144 | influenza, seasonal, intradermal, preservative free | 9/24/2024 | |
| 90656 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 140 | Influenza, split virus, trivalent, PF | 6/13/2024 | |
| 90657 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use | 141 | Influenza, split virus, trivalent, preservative | 6/13/2024 | |
| 90658 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use | 141 | Influenza, split virus, trivalent, preservative | 6/13/2024 | |
| 90659 | Influenza virus vaccine, whole virus, for intramuscular or jet injection use | 16 | influenza, whole | 2/28/2017 | |
| 90660 | Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use | 111 | Influenza, live, trivalent, intranasal | 6/13/2024 | |
| 90661 | Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use | 153 | Influenza, MDCK, trivalent, PF | 9/24/2024 | |
| 90661 | Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use | 320 | Influenza, MDCK, trivalent, preservative | 9/24/2024 | |
| 90662 | Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use | 135 | Influenza, high-dose, trivalent, PF | 6/13/2024 | |
| 90662 | Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use | 197 | Influenza, high-dose, quadrivalent, PF | 6/13/2024 | |
| 90663 | Influenza virus vaccine, pandemic formulation, H1N1 | 128 | Novel Influenza-H1N1-09, all formulations | 2/28/2017 | |
| 90664 | Influenza virus vaccine, live (LAIV), pandemic formulation, for intranasal use | 125 | Novel Influenza-H1N1-09, nasal | 6/13/2024 | |
| 90665 | Lyme disease vaccine, adult dosage, for intramuscular use | 66 | Lyme disease | 2/28/2017 | |
| 90666 | Influenza virus vaccine (IIV), pandemic formulation, split virus, preservative free, for intramuscular use | 126 | Novel influenza-H1N1-09, preservative-free | 6/13/2024 | |
| 90668 | Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use | 127 | Novel influenza-H1N1-09 | 6/13/2024 | |
| 90669 | Pneumococcal conjugate vaccine, 7 valent, for intramuscular use | 100 | pneumococcal conjugate PCV 7 | 2/28/2017 | |
| 90670 | Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 133 | Pneumococcal conjugate PCV 13 | 6/13/2024 | |
| 90671 | Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use | 215 | Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF | 6/13/2024 | |
| 90672 | Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use | 149 | Influenza, live, quadrivalent, intranasal | 6/13/2024 | |
| 90673 | Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use | 155 | Influenza, recombinant, trivalent, PF | 6/13/2024 | |
| 90674 | Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use | 171 | Influenza, MDCK, quadrivalent, PF | 6/13/2024 | |
| 90675 | Rabies vaccine, for intramuscular use | 176 | Rabies - IM fibroblast culture | 6/13/2024 | |
| 90675 | Rabies vaccine, for intramuscular use | 175 | Rabies - IM Diploid cell culture | 6/13/2024 | |
| 90676 | Rabies vaccine, for intradermal use | 40 | rabies, intradermal injection | 6/13/2024 | |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use | 216 | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF | 6/13/2024 | |
| 90678 | Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use | 305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF | CPT Code to be used for ABRYSVO | 6/13/2024 |
| 90679 | Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use | 303 | RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF | CPT Code to be Used for Arexvy | 6/13/2024 |
| 90680 | Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use | 116 | rotavirus, pentavalent | 6/13/2024 | |
| 90681 | Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use | 119 | rotavirus, monovalent | 6/13/2024 | |
| 90682 | Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use | 185 | Influenza, recombinant, quadrivalent, PF | 6/13/2024 | |
| 90683 | Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use | 326 | RSV, mRNA, injectable, PF | 6/13/2024 | |
| 90684 | Pneumococcal conjugate vaccine, 21 valent (PCV21), for intramuscular use | 327 | Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF | 7/9/2024 | |
| 90685 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | 6/13/2024 | |
| 90686 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 150 | Influenza, split virus, quadrivalent, PF | 6/13/2024 | |
| 90687 | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use | 158 | Influenza, split virus, quadrivalent, preservative | 6/13/2024 | |
| 90688 | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 158 | Influenza, split virus, quadrivalent, preservative | 6/13/2024 | |
| 90690 | Typhoid vaccine, live, oral | 25 | typhoid, oral | 6/13/2024 | |
| 90691 | Typhoid vaccine, Vi capsular polysaccharide (ViCPs), for intramuscular use | 101 | typhoid, ViCPs | 6/13/2024 | |
| 90692 | Typhoid vaccine, heat- and phenol-inactivated (H-P), for subcutaneous or intradermal use | 41 | typhoid, parenteral | 2/28/2017 | |
| 90693 | Typhoid vaccine, acetone-killed, dried (AKD), for subcutaneous use (U.S. military) | 53 | typhoid, parenteral, AKD (U.S. military) | 2/28/2017 | |
| 90694 | Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use | 205 | Influenza, adjuvanted, quadrivalent, PF | 6/13/2024 | |
| 90696 | Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use | 130 | DTaP-IPV | 6/13/2024 | |
| 90697 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use | 146 | DTaP,IPV,Hib,HepB | 6/13/2024 | |
| 90698 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use | 120 | DTaP-Hib-IPV | 6/13/2024 | |
| 90700 | Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use | 20 | DTaP | 6/13/2024 | |
| 90700 | Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use | 106 | DTaP, 5 pertussis antigens | 6/13/2024 | |
| 90701 | Diphtheria, tetanus toxoids, and whole cell pertussis vaccine (DTP), for intramuscular use | 01 | DTP | 2/28/2017 | |
| 90702 | Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use | 28 | DT (pediatric) | 6/13/2024 | |
| 90703 | Tetanus toxoid adsorbed, for intramuscular use | 35 | tetanus toxoid, adsorbed | 2/28/2017 | |
| 90704 | Mumps virus vaccine, live, for subcutaneous use | 07 | mumps | 2/28/2017 | |
| 90705 | Measles virus vaccine, live, for subcutaneous use | 05 | measles | 2/28/2017 | |
| 90706 | Rubella virus vaccine, live, for subcutaneous use | 06 | rubella | 2/28/2017 | |
| 90707 | Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use | 03 | MMR | 6/13/2024 | |
| 90708 | Measles and rubella virus vaccine, live, for subcutaneous use | 04 | M/R | 2/28/2017 | |
| 90710 | Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use | 94 | MMRV | 6/13/2024 | |
| 90712 | Poliovirus vaccine, (any type[s]) (OPV), live, for oral use | 182 | OPV, Unspecified | 2/28/2017 | |
| 90713 | Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use | 10 | IPV | 6/13/2024 | |
| 90714 | Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use | 113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | Beginning in 2005, this CPT code maps to TD preservative free. Remapped to CVX code 09 10/2021 to support active products mapped to that code. | 6/13/2024 |
| 90714 | Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use | 09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | Beginning in 2005, this CPT code maps to TD preservative free. Remapped to CVX code 09 10/2021 to support active products mapped to that code. | 6/13/2024 |
| 90715 | Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 115 | Tdap | 6/13/2024 | |
| 90716 | Varicella virus vaccine (VAR), live, for subcutaneous use | 21 | varicella | 6/13/2024 | |
| 90717 | Yellow fever vaccine, live, for subcutaneous use | 37 | yellow fever live | 6/13/2024 | |
| 90717 | Yellow fever vaccine, live, for subcutaneous use | 183 | Yellow fever vaccine live - alt | 6/13/2024 | |
| 90720 | Diphtheria, tetanus toxoids, and whole cell pertussis vaccine and Hemophilus influenza B vaccine (DTP-Hib), for intramuscular use | 22 | DTP-Hib | 2/28/2017 | |
| 90721 | Diphtheria, tetanus toxoids, and acellular pertussis vaccine and Hemophilus influenza B vaccine (DTaP/Hib), for intramuscular use | 50 | DTaP-Hib | 2/28/2017 | |
| 90723 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use | 110 | DTaP-Hep B-IPV | 6/13/2024 | |
| 90724 | Influenza virus vaccine | 88 | influenza, unspecified formulation | 3/3/2017 | |
| 90725 | Cholera vaccine for injectable use | 26 | cholera, unspecified formulation | 2/28/2017 | |
| 90727 | Plague vaccine, for intramuscular use | 23 | plague | 2/28/2017 | |
| 90728 | BCG vaccine | 19 | BCG | 3/3/2017 | |
| 90730 | Hepatitis A vaccine | 85 | Hep A, unspecified formulation | 3/3/2017 | |
| 90731 | Hepatitis B vaccine | 45 | Hep B, unspecified formulation | 3/3/2017 | |
| 90732 | Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use | 33 | pneumococcal polysaccharide PPV23 | 6/13/2024 | |
| 90733 | Meningococcal polysaccharide vaccine, serogroups A, C, Y, W-135, quadrivalent (MPSV4), for subcutaneous use | 32 | meningococcal MPSV4 | 6/13/2024 | |
| 90734 | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use | 114 | meningococcal MCV4P | 6/13/2024 | |
| 90734 | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use | 136 | Meningococcal MCV4O | 6/13/2024 | |
| 90735 | Japanese encephalitis virus vaccine, for subcutaneous use | 39 | Japanese encephalitis SC | 2/28/2017 | |
| 90736 | Zoster (shingles) vaccine (HZV), live, for subcutaneous injection | 121 | zoster live | 6/13/2024 | |
| 90737 | Hemophilus influenza B | 17 | Hib, unspecified formulation | 3/3/2017 | |
| 90738 | Japanese encephalitis virus vaccine, inactivated, for intramuscular use | 134 | Japanese Encephalitis IM | 6/13/2024 | |
| 90739 | Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule, for intramuscular use | 189 | HepB-CpG | 6/13/2024 | |
| 90740 | Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use | 44 | Hep B, dialysis | 6/13/2024 | |
| 90741 | Immunization, passive; immune serum globulin, human (ISG) | 14 | IG, unspecified formulation | 3/3/2017 | |
| 90743 | Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use | 43 | Hep B, adult | 6/13/2024 | |
| 90744 | Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use | 08 | Hep B, adolescent or pediatric | 6/13/2024 | |
| 90745 | Hepatitis B vaccine, adolescent/high risk infant dosage, for intramuscular use | 42 | Hep B, adolescent/high risk infant | 3/3/2017 | |
| 90746 | Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use | 43 | Hep B, adult | 6/13/2024 | |
| 90747 | Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use | 43 | Hep B, adult | Note that the NDCs for Engerix-B are mapped to CVX 43 which is not specific to dialysis use | 6/13/2024 |
| 90748 | Hepatitis B and Haemophilus influenzae type b vaccine (Hib-HepB), for intramuscular use | 51 | Hib-Hep B | 6/13/2024 | |
| 90750 | Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use | 187 | zoster recombinant | 6/13/2024 | |
| 90756 | Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use | 186 | Influenza, MDCK, quadrivalent, preservative | Effective 1/1/2018 | 6/13/2024 |
| 90758 | Zaire ebolavirus vaccine, live, for intramuscular use | 204 | Ebola Zaire vaccine, live, recombinant, 1mL dose | 6/13/2024 | |
| 90759 | Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use | 220 | HepB recombinant, 3-antigen, Al(OH)3 | 6/13/2024 | |
| 91300 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use | 208 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | COVID-19 Vaccine - EUA authorized 12/11/2020 | 6/13/2024 |
| 91301 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use | 207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | COVID-19 Vaccine - BLA Licensed and EUA authorized | 6/13/2024 |
| 91302 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use | 210 | COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL | COVID-19 Vaccine - EUA submission withdrawn | 6/13/2024 |
| 91303 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use | 212 | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL | COVID-19 Vaccine - EUA authorized 2/27/2021 | 6/13/2024 |
| 91304 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use | 211 | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | Original and Fall COVID-19 vaccine starting 2023 | 9/24/2024 |
| 91304 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use | 313 | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL | Original and Fall COVID-19 vaccine starting 2023 | 9/24/2024 |
| 91305 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | 217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | COVID-19 Vaccine - EUA authorized for primary series and IC, EUA rescinded 8/31/202 for monovalent boosters | 6/13/2024 |
| 91306 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use | 207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | COVID-19 Vaccine - EUA authorization rescinded 8/31/2022 for adult monovalent booster dose | 6/13/2024 |
| 91307 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | 218 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose | COVID-19 Vaccine - EUA authorized, pediatric 5 yrs through 11 yrs dose requires dilution | 6/13/2024 |
| 91308 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | 219 | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose | COVID-19 Vaccine - EUA authorized for children under 5 yrs | 6/13/2024 |
| 91309 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use | 221 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose | COVID-19 Vaccine - EUA authorized for pediatric, EUA rescinded 8/31/2022 for adult monovalent booster dose | 6/13/2024 |
| 91310 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use | 225 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL | COVID-19 Vaccine - Potential EUA authorization booster dose | 6/13/2024 |
| 91311 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use | 228 | COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose | COVID-19 Vaccine - EUA authorized for ages 6 mo through 5 yrs | 6/13/2024 |
| 91312 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | 300 | COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose | COVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster ages 12+ yrs | 6/13/2024 |
| 91313 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use | 229 | COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose | COVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster for ages 18+ yrs, potential EUA ages 6 yrs through 17 yrs | 6/13/2024 |
| 91314 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use | 229 | COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose | COVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster for ages 6 yrs through 11 yrs | 6/13/2024 |
| 91315 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | 301 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose | COVID-19 Vaccine - Potential EUA authorization bivalent booster for ages 5 yrs through 11 yrs | 6/13/2024 |
| 91316 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use | 230 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL | COVID-19 Vaccine - EUA authorized 12/8/2022 bivalent booster (Moderna) for ages 6 mo through 5 yrs | 6/13/2024 |
| 91317 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | 302 | COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose | COVID-19 Vaccine - EUA authorized 12/8/2022 bivalent vaccine (Pfizer) for ages 6 mo through 4 yrs | 6/13/2024 |
| 91318 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | 308 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL | Fall COVID-19 vaccine starting 2023 | 9/24/2024 |
| 91319 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | 310 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL | Fall COVID-19 vaccine starting 2023 | 9/24/2024 |
| 91320 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | 309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | Fall COVID-19 vaccine starting 2023 | 9/24/2024 |
| 91321 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use | 311 | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | Fall COVID-19 vaccine starting 2023 | 9/24/2024 |
| 91322 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use | 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | Fall COVID-19 vaccine starting 2023 | 9/24/2024 |
CPT codes are developed and maintained by the American Medical Association (AMA) and are intended to support billing for services. CPT codes have been reproduced here with permission from the AMA. CPT five-digit codes, nomenclature and other data are Copyright, American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in this cross-reference. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS restrictions apply to government use.
CVX codes are codes that indicate the product used in a vaccination. They are maintained by the Centers for Disease Control and Prevention, Immunization Information System Support Branch (IISSB) for use in HL7 data transmission.
Questions regarding this table should be directed to the IIS Technical Assistance Team; CDC, National Centers for Immunization and Respiratory Diseases, Immunization Information Systems Support Branch-Informatics, 1600 Clifton Road, Mailstop E-62, Atlanta, GA 30333.
For further information on HL7 immunization data exchange and the CVX code set, contact the IIS Technical Assistance Team at:
Address:
CDC, National Centers for Immunization and Respiratory DiseasesEmail:
Immunization Information System Support Branch - Informatics
1600 Clifton Road
Mailstop: E-62
Atlanta, GA 30333
iisinfo@cdc.gov (note change)
Page last reviewed: October 24, 2024
Content source: National Center for Immunization and Respiratory Diseases